lenvatinib_Gupta_26879594
Indication: Advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer
Population PK simulator for lenvatinib (Lenvima) based on 3-compartment model from Gupta et al. (2016). Explore dose-exposure relationships with CYP3A4 interactions, weight, and hepatic function covariates.
Drug Overview
Clinical Context
- Drug Class
- Multikinase Inhibitor (TKI)
- Therapeutic Area
- Oncology
- Indication
- Advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer
Model Information
- Model Type
- Population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for lenvatinib_Gupta_26879594 allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK model characterizes the pharmacokinetics of this multikinase inhibitor (tki).
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the lenvatinib_Gupta_26879594 PK simulator?
This is a free, interactive pharmacokinetic simulator for lenvatinib_Gupta_26879594 used in Advanced renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does lenvatinib_Gupta_26879594 belong to?
lenvatinib_Gupta_26879594 is classified as a Multikinase Inhibitor (TKI). It is used in the Oncology therapeutic area.
What type of PK model is used?
This simulator uses a Population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
PopPK of Docetaxel
capecitabine
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the lenvatinib_Gupta_26879594 simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community